azilsartan medoxomil potassium: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
azilsartan medoxomil potassium: clinical details
Prescribing considerations
- Licensed for essential hypertension in adults; not indicated for people under 18 years.
- Correct significant volume or salt depletion and assess hypotension risk before initiation.
- Use caution where renal function depends on the renin–angiotensin system, including severe renal impairment, renal artery stenosis or heart failure.
- Use is not recommended in severe hepatic impairment or primary hyperaldosteronism; experience after recent kidney transplantation is lacking.
- Use particular caution with aortic or mitral stenosis, obstructive hypertrophic cardiomyopathy, or ischaemic cardiac or cerebrovascular disease.
- Dual renin–angiotensin system blockade is generally not recommended and, if exceptionally necessary, requires specialist supervision.
Contraindications and cautions
- Hypersensitivity to azilsartan medoxomil or an excipient.
- Second or third trimester of pregnancy.
- Use with an aliskiren-containing product in diabetes mellitus or renal impairment with GFR below 60 mL/min/1.73 m².
Monitoring
- Check blood pressure, renal function, serum potassium and sodium before treatment.
- Recheck renal function and electrolytes after initiation or treatment changes, and sooner in people at increased risk.
- Continue periodic renal-function and electrolyte monitoring once stable; increase monitoring during acute illness or when interacting medicines are introduced.
- Investigate clinically important creatinine rises, declining eGFR, hyperkalaemia or symptomatic hypotension, including volume depletion and interacting medicines such as NSAIDs.
Clinical pharmacology
Azilsartan medoxomil is rapidly hydrolysed to active azilsartan, a selective AT1-receptor antagonist. It blocks angiotensin II-mediated vasoconstriction, aldosterone release and renal sodium reabsorption. Food does not materially affect azilsartan bioavailability, and the active compound is highly protein-bound.
Formulation and product differences
- The selected products are white, round oral tablets; tablet size and debossed markings distinguish the available strengths.
- The tablets contain azilsartan medoxomil as the potassium salt and are essentially sodium-free.
- Store in the original package to protect from light and moisture.
azilsartan medoxomil potassium interactions
Check prescribed, over-the-counter and complementary products with a pharmacist or prescriber. Important interactions include:
Lithium
Azilsartan may increase lithium concentrations and toxicity. The combination is not recommended unless specialist monitoring is arranged.
NSAIDs, including ibuprofen, diclofenac and selective COX-2 inhibitors
They may reduce the blood-pressure effect and increase the risks of kidney impairment and raised potassium.
Potassium supplements, potassium-containing salt substitutes and potassium-sparing diuretics
These can raise blood potassium and may require laboratory monitoring.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.